NCT03223896View on ClinicalTrials.gov

Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
GamblingOpioidNaloxoneSpray
Interventions
DRUG

Naloxone hydrochloride 20mg/ml

Nasal spray

Trial Locations (1)

00271

National Institute for Heath and Welfare, Helsinki

All Listed Sponsors
lead

Finnish Institute for Health and Welfare

OTHER_GOV

NCT03223896 - Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray | Biotech Hunter | Biotech Hunter